OnCo
companiesCompany

Rigel Pharmaceuticals

Commercialises olutasidenib (Rezlidhia), an IDH1 inhibitor for relapsed AML, alongside fostamatinib.

Olutasidenib approved 1 December 2022 for relapsed/refractory IDH1-mutated AML (CR+CRh 35% in the pivotal cohort). Rigel licensed it from Forma Therapeutics/Novo Nordisk in 2022.

Headquarters
South San Francisco, CA, US
Type
biotech · RIGL

Products

1top
ApprovedSmall-molecule IDH1 inhibitor
Olutasidenib · Rezlidhia

Olutasidenib is a second IDH1 inhibitor for relapsed AML, with a higher response rate in its pivotal cohort than ivosidenib had in its own.

Connected

3top

Pages like this

not linked directly; found by shared links

cancers

1
Acute myeloid leukaemia

fronts

1
Targeted Therapy

drugs

1
ApprovedSmall-molecule IDH1 inhibitor
Olutasidenib · Rezlidhia